XML 41 R27.htm IDEA: XBRL DOCUMENT
v3.26.1

STOCKHOLDERS’ EQUITY (DEFICIENCY) (Tables) | 9 Months Ended
--- | ---
Mar. 31, 2026
Equity [Abstract] |
SCHEDULE OF WARRANT EXERCISES | SCHEDULE OF WARRANT EXERCISES
|  |  |  |  | Three Months Ended March 31, 2026 |  |  | Nine Months Ended March 31, 2026 |
Series |  | Exercise Price |  |  | Warrants |  |  | Proceeds |  |  | Warrants |  |  | Proceeds |
Series F Warrants |  | $ | 15.00 |  |  |  | - |  |  | $ | - |  |  |  | 16,866 |  |  | $ | 252,990 |
Series G Warrants |  | $ | 7.50 |  |  |  | 3,168 |  |  |  | 23,760 |  |  |  | 79,092 |  |  |  | 593,197 |
Series H Warrants |  | $ | 11.25 |  |  |  | 900 |  |  |  | 10,125 |  |  |  | 31,499 |  |  |  | 354,364 |
Series J Warrants |  | $ | 6.50 |  |  |  | 10,000 |  |  |  | 65,000 |  |  |  | 29,984 |  |  |  | 194,896 |
Series K Warrants |  | $ | 8.125 |  |  |  | 5,000 |  |  |  | 40,625 |  |  |  | 24,984 |  |  |  | 202,994 |
|  |  |  |  |  |  | 19,068 |  |  | $ | 139,510 |  |  |  | 182,425 |  |  | $ | 1,598,441 |
SCHEDULE OF OUTSTANDING STOCK PURCHASE WARRANTS | As of March 31, 2026, the Company had outstanding warrants for shares of common stock as follows: SCHEDULE OF OUTSTANDING STOCK PURCHASE WARRANTS
|  | Shares of Common |  |  | Exercise Price per |  |  | Latest Expiration
Description |  | Stock |  |  | Share |  |  | Date
May 2022 Warrants |  |  | 1,333 |  |  | $ | 625.00 |  |  | May 11, 2026
October 2022 Placement Agent Warrants |  |  | 1,818 |  |  | $ | 10.00 |  |  | October 31, 2027
October 2023 Placement Agent Warrants |  |  | 2,358 |  |  | $ | 10.00 |  |  | October 20, 2028
January 2024 Private Warrants |  |  | 36,630 |  |  | $ | 273.00 |  |  | February 1, 2028
January 2024 Placement Agent Warrants |  |  | 1,831 |  |  | $ | 10.00 |  |  | February 1, 2028
June 2024 Series B Warrants |  |  | 37,712 |  |  | $ | 94.00 |  |  | July 25, 2030*
December 2024 Series C Warrants |  |  | 78,153 |  |  | $ | 43.75 |  |  | December 17, 2029
December 2024 Series D Warrants |  |  | 39,076 |  |  | $ | 43.75 |  |  | July 25, 2030
February 2025 Series E Warrants |  |  | 93,760 |  |  | $ | 50.00 |  |  | August 12, 2030
May 2025 Series F Warrants |  |  | 129,613 |  |  | $ | 15.00 |  |  | May 8, 2030
May 2025 Series G Warrants |  |  | 67,387 |  |  | $ | 7.50 |  |  | May 8, 2027
May 2025 Series H Warrants |  |  | 47,593 |  |  | $ | 11.25 |  |  | -**
June 2025 Series I Warrants |  |  | 123,636 |  |  | $ | 5.50 |  |  | July 25, 2030
November 2025 Pre-funded Warrants |  |  | 2,136,000 |  |  | $ | 0.0001 |  |  | N/A
November 2025 Series J Warrants |  |  | 2,765,400 |  |  | $ | 6.50 |  |  | -***
November 2025 Series K Warrants |  |  | 2,770,400 |  |  | $ | 8.13 |  |  | -****
November 2025 Placement Agent Warrants |  |  | 55,907 |  |  | $ | 8.13 |  |  | November 12, 2030
November 2025 HCW Settlement Warrants |  |  | 10,000 |  |  | $ | 10.00 |  |  | January 12, 2028
* |  | 5,228 warrants expire June 24, 2029
** |  | Expire 24 months following the intial exercise date
*** |  | Expires the earlier of (i) the 18-month anniversary of the Initial Exercise Date if FDA IND acceptance has not been received, or (ii) 31 days after notice of FDA IND acceptance, in each case adjusted to the next Trading Day; provided that under clause (ii) the date is extended until a registration statement and prospectus are available for 30 consecutive days.
**** |  | Expire on the 5-year anniversary of the Initial Exercise Date, or, if the Holder’s Series J Common Stock Purchase Warrant terminates pursuant to clause (ii) thereof prior to full cash exercise, the same Termination Date as the Series J Warrant, in each case adjusted to the next Trading Day; provided that the date is extended until a registration statement and prospectus are available for 30 consecutive days following notice of FDA IND acceptance.
SCHEDULE OF STOCK OPTION ACTIVITY | A summary of stock option activity is as follows: SCHEDULE OF STOCK OPTION ACTIVITY
|  | Number of Shares |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Term in Years |  |  | Aggregate Intrinsic Value |
Outstanding - June 30, 2025 |  |  | 44,805 |  |  | $ | 302.00 |  |  |  | 7.3 |  |  |  |  |
Granted |  |  | 39,550 |  |  |  | 21.38 |  |  |  |  |  |  |  |  |
Fractional shares |  |  | (14 | ) |  |  |  |  |  |  |  |  |  |  |  |
Forfeited |  |  | (1,266 | ) |  |  | 76.33 |  |  |  |  |  |  |  |  |
Exercised |  |  | - |  |  |  | - |  |  |  |  |  |  |  |  |
Expired |  |  | (4,497 | ) |  |  | 480.12 |  |  |  |  |  |  |  |  |
Outstanding - March 31, 2026 |  |  | 78,578 |  |  | $ | 159.01 |  |  |  | 8.1 |  |  | $ | - |
Exercisable at March 31, 2026 |  |  | 24,307 |  |  | $ | 407.50 |  |  |  | 5.8 |  |  | $ | - |
Expected to vest at March 31, 2026 |  |  | 54,271 |  |  | $ | 46.53 |  |  |  | 9.2 |  |  | $ | - |
SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY | A summary of RSU activity is as follows: SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY
Outstanding at June 30, 2025 |  |  | 22,787 |
Granted |  |  | 24,950 |
Forfeited |  |  | - |
Vested |  |  | (6,467 | )
Expirations |  |  | (1,254 | )
Fractional shares |  |  | - |
Outstanding at March 31, 2026 |  |  | 40,016 |

X
- Definition Schedule of Stock Purchase Warrants [Table Text Block] + References No definition available. + Details
Name: | PTN_ScheduleOfStockPurchaseWarrantsTableTextBlock
Namespace Prefix: | PTN_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Schedule of Warrant Exercises [Table Text Block] + References No definition available. + Details
Name: | PTN_ScheduleOfWarrantExercisesTableTextBlock
Namespace Prefix: | PTN_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration